Last updated: April 24, 2026
What Is the Patent Scope and Claim Coverage for CN103284984 and How Does It Sit in the China Landscape?
CN103284984 is a Chinese patent publication that covers a defined pharmaceutical subject matter and has a limited, trackable scope in China based on its bibliographic record. However, a complete and accurate claim-by-claim scope map requires the full published specification text (claims section and independent/dependent claim set), as well as related family members and legal status events. Without that full text, any claim coverage characterization would risk fabricating or misattributing claim elements.
What Does CN103284984 Cover at the Claim Level?
A claim-level scope analysis needs the actual claim language from CN103284984 (independent claims, dependent claims, definitions in the description tied to those claims, and the claim numbering). This analysis cannot be produced from bibliographic metadata alone.
What Is the Practical Scope in China Litigation and Clearance Terms?
A practical scope view also depends on:
- Claim form (product vs. process vs. use)
- Claim breadth drivers (Markush groups, ranges, generics with genus limits, functional limitations)
- Chemical/material definitions (structural formula coverage, salts, polymorphs, hydrates, stereoisomers)
- Method-of-treatment or dosing regimens
- Any explicit exclusions or preferred embodiments used to narrow interpretation
These elements require the text of the claims and, in many cases, the claim construction signals from the specification.
How Does the CN103284984 Patent Sit in the China Patent Landscape?
A landscape placement requires:
- Patent family mapping (priority, continuations, and counterpart jurisdictions)
- Current legal status in China (in force, expired, withdrawn, lapsed, invalidated, or surrendered)
- Any linkage to drug approvals (NMPA approval dossiers and generic application status)
- Citations and forward citations showing which later CN applications and patents rely on or distinguish the same subject matter
These items also require access to the published record and legal status and citation data associated with CN103284984.
What Are the Key Competitor and Design-Around Vectors in China?
Design-around vectors depend on what CN103284984 actually claims. Common vectors in China for drug-related patents include:
- Switching from one salt/hydrate/polymorph to another
- Using different stereoisomers or mixtures with different ratios
- Changing synthesis route if the claims are process-limited
- Avoiding claimed functional parameters (e.g., particle size, dissolution profile, stability windows)
- Switching the compound class outside the claimed genus boundary
But the presence or absence of those vectors for CN103284984 cannot be concluded without the claim text.
What Coverage Metrics Can Be Quantified?
With full claim text, a coverage map typically produces quantified metrics such as:
- Number of independent claims
- Number of dependent claims
- Breadth of chemical genus (count of disclosed members vs. claim-restricted members)
- Presence of numeric ranges and their span
- Whether claims are directed to active ingredient only, compositions, or therapeutic uses
- Whether claims cover formulation parameters (excipients, dosage forms) or only the API
- Whether claims include alternative definitions that broaden scope (e.g., “including” with open lists)
None of these metrics can be computed reliably without the publication’s claims section.
Key Takeaways
- CN103284984’s scope cannot be accurately analyzed at the claim level without the actual published claims and specification text.
- A meaningful China landscape placement (family mapping, legal status, citations, and design-around vectors) likewise requires access to the full publication record and legal status data.
- Any “detailed analysis” of scope and claim coverage delivered without those claim texts would risk misstatement.
FAQs
-
Can a claim-by-claim scope map be generated from CN103284984’s bibliographic data alone?
No. Claim coverage analysis requires the published claims’ exact language and structure.
-
What determines whether competitors can design around a CN drug patent in China?
The claim type (compound, salt/form, composition, use, or process), the breadth drivers (Markush/ranges/functional limits), and whether the claims cover formulations or only the active.
-
How is CN drug-patent “landscape” usually evaluated for enforcement risk in China?
By combining family scope, current legal status, forward citations, and linkage to NMPA approval and generic application timelines.
-
Do formulation patents matter as much as API patents in China?
They can, especially if the claims cover dosage forms and composition parameters that generics must replicate to launch, or if the claims include process parameters tied to the final product.
-
What is the fastest way to assess infringement exposure for a molecule in China?
Map each independent claim element to the product/process details, then test each element against likely design-around parameters (salt/polymorph/stereochemistry/composition/use).
References (APA)
[1] CN103284984. (n.d.). Chinese patent publication record. (Source not provided in the prompt.)
